Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07451665) titled 'Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis' on Feb. 28.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Chinese SLE Treatment And Research Group
Condition:
Takayasu Arteritis (TAK)
Intervention:
Drug: Vanakizumab
Drug: Ivarmacitinib
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: April 1, 2026
Target Sample Size: 180
Countries of Recruitment:
China
To know more, visit https://clinicaltri...